Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

The meningeal lymphatic system: a route for HIV brain migration?

Lamers SL, Rose R, Ndhlovu LC, Nolan DJ, Salemi M, Maidji E, Stoddart CA, McGrath MS.

J Neurovirol. 2016 Jun;22(3):275-81. doi: 10.1007/s13365-015-0399-y. Epub 2015 Nov 16. Review.

PMID:
26572785
2.

Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders.

Giancola ML, Lorenzini P, Cingolani A, Baldini F, Bossolasco S, Bini T, Monno L, Picchi G, d'Arminio Monforte A, Cinque P, Tozzi V, Antinori A.

AIDS Res Treat. 2012;2012:708456. doi: 10.1155/2012/708456. Epub 2012 Aug 26.

3.

Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research.

Cysique LA, Waters EK, Brew BJ.

BMC Neurol. 2011 Nov 22;11:148. doi: 10.1186/1471-2377-11-148. Review.

4.

Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.

Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA; UK Collaborative HIV Cohort (CHIC) study..

Neurology. 2011 Feb 22;76(8):693-700. doi: 10.1212/WNL.0b013e31820d8b0b.

5.

Neurocognitive impairment and HIV risk factors: a reciprocal relationship.

Anand P, Springer SA, Copenhaver MM, Altice FL.

AIDS Behav. 2010 Dec;14(6):1213-26. doi: 10.1007/s10461-010-9684-1. Review.

6.

Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.

Hightower GK, Letendre SL, Cherner M, Gibson SA, Ellis RJ, Wolfson TJ, Gamst AC, Ignacio CC, Heaton RK, Grant I, Richman DD, Smith DM; HNRC Group..

Virology. 2009 Nov 25;394(2):243-8. doi: 10.1016/j.virol.2009.08.007. Epub 2009 Sep 16.

7.

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.

Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ.

Neurology. 2009 Aug 4;73(5):342-8. doi: 10.1212/WNL.0b013e3181ab2b3b. Epub 2009 May 27.

8.

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.

Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K; AIDS Clinical Trials Group 736 Study Team..

AIDS. 2009 Jul 17;23(11):1359-66. doi: 10.1097/QAD.0b013e32832c4152.

9.

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group..

Arch Neurol. 2008 Jan;65(1):65-70. doi: 10.1001/archneurol.2007.31.

11.

Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW.

BMC Infect Dis. 2005 Nov 2;5:98.

Supplemental Content

Support Center